Tag: Car-T

The Promise of RNA-Based Therapies

Published a day ago Submitted by CRB Decades of scientific progress in understanding the root cause of many formerly intractable diseases has opened up new treatment options, namely through RNA-based therapies. This second wave of biopharma, in which our understanding of the ways coding portions of our genome relate to…

Continue Reading The Promise of RNA-Based Therapies

Phase 1 Trial to Test ‘Off-the-shelf’ CAR T-cell Therapy CB-011 in 2023 | CAR T-cell Therapy CB-011 to Be Tested in Hard-to-treat Myeloma in 2023

Caribou Biosciences will soon start testing its new CAR T-cell therapy candidate, CB-011, in people with relapsed or refractory multiple myeloma. A Phase 1 trial will begin enrolling eligible adults in early 2023 at multiple centers, according to the company. The announcement follows clearance of the company’s investigational new drug…

Continue Reading Phase 1 Trial to Test ‘Off-the-shelf’ CAR T-cell Therapy CB-011 in 2023 | CAR T-cell Therapy CB-011 to Be Tested in Hard-to-treat Myeloma in 2023

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line. New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in addition to chimeric antigen receptor (CAR) T-cell therapy,…

Continue Reading Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

Lessons From ZUMA-7, BELINDA, and TRANSFORM

Dr. Brad Kahl Key Points: Historically, patients with diffuse large B-cell lymphoma (DLBCL) for whom frontline and salvage chemotherapy had failed had little chance of cure; now, 3 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—show promising prolonged disease-free survival. The ZUMA-7, BELINDA, and TRANSFORM trials compared…

Continue Reading Lessons From ZUMA-7, BELINDA, and TRANSFORM

advantages of electroporation

Therapeutic mRNAs can be stabilized by the incorporation of modified nucleosides, synthetic capping, and the addition of lengthy poly-A tails, and can be enhanced with codon optimization (1113). Maintains viability . Plant tissue culture is a collection of techniques used to maintain or grow plant cells, tissues or organs under…

Continue Reading advantages of electroporation

Inceptor Bio And Avectas Patner To Improve The Development & Manufacturing Of CAR-T Cell Therapies

Inceptor Bio, a cell therapy biotechnology company, and Avectas, a cell engineering technology leader, have partnered to improve the development and manufacturing of next-generation CAR-T cell therapies for the treatment of solid tumors.   Under the agreement, Inceptor will utilize Avectas’ SOLUPORE technology as an alternative to electroporation for engineering…

Continue Reading Inceptor Bio And Avectas Patner To Improve The Development & Manufacturing Of CAR-T Cell Therapies

Celyad Oncology (NASDAQ:CYAD) Shares Cross Below Fifty Day Moving Average of $1.88

Celyad Oncology SA (NASDAQ:CYAD – Get Rating)’s stock price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.88 and traded as low as $1.84. Celyad Oncology shares last traded at $1.84, with a volume of 9,089 shares…

Continue Reading Celyad Oncology (NASDAQ:CYAD) Shares Cross Below Fifty Day Moving Average of $1.88

Global Gene Therapy R&D Market Worth US$ 22,685.70 million by 2031: Visiongain Reports Ltd

Visiongain Reports Ltd Global Gene Therapy R&D Market Forecast 2021-2031: – Market Segment by Disease {Cancer, Rare Diseases (Oncologic, Non-Oncologic), Cardiovascular Diseases, Ophthalmic Diseases, Hematology, Neurological, Diabetes Mellitus, Other Diseases}, Vector {Viral (Retrovirus, Adenovirus, AAV, Lentivirus, Others), Non-Viral (Naked DNA, Gene Gun, Electroporation, Lipofection)}, Techniques (Gene Augmentation Therapy, Gene Replacement…

Continue Reading Global Gene Therapy R&D Market Worth US$ 22,685.70 million by 2031: Visiongain Reports Ltd

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences, Inc. BERKELEY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi 17th Annual BioPharma Conference, BostonPanel participation on September 8, 2022, 11:20 am ETWebcast H.C. Wainwright 24th…

Continue Reading Caribou Biosciences to Participate in Upcoming Investor Conferences

Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations

Joseph E Maakaron, assistant professor of medicine, Marie Hu, assistant professor of medicine, Najla El Jurdi, assistant professor of medicine University of Minnesota Twin Cities, Minneapolis, United States Correspondence to: maaka001{at}umn.edu Abstract Chimeric antigen receptor T cells have revolutionized the treatment of hematological malignancies during the past five years, boasting…

Continue Reading Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations

Stifel Raises Price Target for CRISPR Therapeutics (CRSP) to $69

Benjamin Burnett, an analyst at Stifel, increased his price objective for CRISPR Therapeutics (NASDAQ: CRSP) to $69.00 (from $55.00) while keeping a Hold rating on the stock. Jay Olson, an analyst at Oppenheimer, reduced his price objective for CRISPR Therapeutics (NASDAQ: CRSP) on November 4, 2021, from $185.00 to $172.00…

Continue Reading Stifel Raises Price Target for CRISPR Therapeutics (CRSP) to $69

Cancer vaccines for next generation are available for personal use

Through biomarkers and, increasingly, gene sequencing, we have seen significant advances in disease diagnosis. These advances have enhanced our ability to characterize diseases at the molecular level, and they allow us to uncover ever more subtle distinctions between cancerous cells and normal cells. This addition has prompted significant improvements in…

Continue Reading Cancer vaccines for next generation are available for personal use

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the ‘Company’), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced an update on its financial results and recent business developments for the first half ended June…

Continue Reading Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

US approves BMS CAR-T in large B-cell lymphoma

Samit Hirawat, medical director of Bristol Myers Squibb. Bristol Myers Squibb has announced that the US Drug Evaluation Agency (FDA) has approved Breyanzi (lisocabtagene maraleucel; lisa-cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with large B-cell lymphoma (DLB), including diffuse large B-cell lymphoma…

Continue Reading US approves BMS CAR-T in large B-cell lymphoma

Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

liulolo/iStock via Getty Images Investment Thesis If you had invested in the CRISPR / Cas9 gene editing pioneer Intellia Therapeutics (NASDAQ:NTLA) five years ago, you would likely be well satisfied with your return to date – a ~285% return on your investment – although you may also feel that it…

Continue Reading Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

Lepton Pharmaceutical LTD is a biotechnology company developing a proprietary, breakthrough technology (Castling Technology) to substantially improve adaptive cell-mediated immune response (T-cells, CAR-T-cells, NK-cells.) Dr. Daniel Zurr, CEO of Lepton said: “We are very pleased to establish this relationship and license agreement with ERS Genomics. It will greatly assist us…

Continue Reading ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

ASCT is no longer suitable for the majority of patients with DLBCL

Most patients with diffuse large B-cell lymphoma (DLBCL) do not experience significant benefit from treatment with autologous stem cell transplantation (ASCT) and better treatment options are currently available for this population, according to a presentation at the Pan Pacific Lymphoma Conference 2022.1 “ASCT is lousy therapy in the modern age,”…

Continue Reading ASCT is no longer suitable for the majority of patients with DLBCL

LG Chem licensing electroporation tech from MaxCyte

LG Chem may have non-exclusive medical and business rights to make use of MaxCyte’s Circulate Electroporation know-how and ExPERT platform. In line with MaxCyte, the partnership will assist LG Chem’s CAR-T packages for strong tumors, together with LR19023, which is within the pre-clinical stage and being developed as a strong…

Continue Reading LG Chem licensing electroporation tech from MaxCyte

Caribou Biosciences Announces – GuruFocus.com

BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. ( CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors. Mr. Johnson is a seasoned executive with 30 years of commercial and operational experience in the biopharmaceutical…

Continue Reading Caribou Biosciences Announces – GuruFocus.com

Novartis announces promising five-year data for leukaemia treatment Kymriah

Novartis has shared long-term, five-year follow-up results from its pivotal clinical phase 2 trial, ELIANA, evaluating Kymriah (tisagenlecleucel), the first-ever approved CAR T-cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL). Kymriah is a one-off treatment designed to help patients’ immune…

Continue Reading Novartis announces promising five-year data for leukaemia treatment Kymriah

Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing

A group of researchers at Children’s Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing, which is designed to allow for precise editing of the CART with less risk of unwanted and unforeseen outcomes that may…

Continue Reading Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing

CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this report. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of…

Continue Reading CALITHERA BIOSCIENCES, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

Senior Research Associate, Bioinformatics at Kite Pharma

Job details Job type full-time Full job description Job description At kite pharma we are revolutionizing the treatment for cancers through immunotherapy through novel breakthrough technologyWe have developed and launched best in class car-t therapy yescarta, currently curing patients from previously intractable b-cell malignanciesWe are using our expertise to apply…

Continue Reading Senior Research Associate, Bioinformatics at Kite Pharma

Enabling genome editing research | Scientist Live

As researchers using genome editing tools move from basic research to clinical settings, high-quality ancillary materials and documentation are critical. To help researchers meet stringent quality requirements, Thermo Fisher Scientific introduced the new GMP-manufactured Gibco CTS TrueCut Cas9 Protein. TrueCut Cas9 proteins are manufactured with United States Pharmacopeia standards in…

Continue Reading Enabling genome editing research | Scientist Live

Diffuse Large B-Cell Lymphoma: Causes, Symptoms, Treatment

Diffuse large B-cell lymphoma (DLBCL) is a cancer of the B cells of the lymphatic system. B cells are responsible for producing antibodies, which are highly specific proteins that fight against bacterial and viral infections. When cancer develops in the B cells, it is called a B-cell lymphoma. B-cell lymphoma…

Continue Reading Diffuse Large B-Cell Lymphoma: Causes, Symptoms, Treatment

Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCL

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion in favor of the approval of polatuzumab vedotin for use in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone in patients with previously untreated diffuse large B-cell lymphoma. The European Medicines Agency’s Committee for…

Continue Reading Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCL

Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL

During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy. Targeted OncologyTM: What are the recommended approaches for relapsed/refractory DLBCL in the second-line and subsequent therapies settings?…

Continue Reading Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL

A genome-scale screen for synthetic drivers of T cell proliferation

Abramson, J. S. et al. Transcend NHL 001: immunotherapy with the CD19-directed CAR T-cell product JCAR017 results in high complete response rates in relapsed or refractory B-cell non-Hodgkin lymphoma. Blood 128, 4192–4192 (2016). Google Scholar  Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators…

Continue Reading A genome-scale screen for synthetic drivers of T cell proliferation

BTG2 gene predicts poor outcome in PT-DLBCL

Introduction Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive form of mature B-cell lymphoma.1–3 PT-DLBCL was the most common type of testicular tumor in men aged over 60 and characterized by painless uni- or bilateral testicular masses with infrequent constitutional symptoms.4–6 PT-DLBCL shows significant extranodal tropism,…

Continue Reading BTG2 gene predicts poor outcome in PT-DLBCL

Caribou Biosciences to Present at Upcoming Investor Conferences

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer,…

Continue Reading Caribou Biosciences to Present at Upcoming Investor Conferences

Dublin, Ireland | Bioinformatics Research Fellow: Understanding the production of CAR-T cell therapies

Job:Dublin, Ireland | Bioinformatics Research Fellow: Understanding the production of CAR-T cell therapies 0 Cell therapy is the transfer of intact, live cells into a patient to treat or cure a disease. Cell-based immunotherapy and in particular, modified-cell immunotherapy such as CAR-T, has been delivering spectacular results for cancer patients…

Continue Reading Dublin, Ireland | Bioinformatics Research Fellow: Understanding the production of CAR-T cell therapies

Bristol Myers’ (BMY) Breyanzi sBLA Gets FDA’s Priority Review

This story originally appeared on Zacks Bristol-Myers Squibb Company BMY announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking approval for its CD19-directed CAR-T cell therapy, Breyanzi (lisocabtagene maraleucel), for an expanded use. – Zacks The sBLA seeks approval of Breyanzi…

Continue Reading Bristol Myers’ (BMY) Breyanzi sBLA Gets FDA’s Priority Review

Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

February 16, 2022 3 min read Source/Disclosures Published by: Source: van Meerten T, et al. Abstract PT02-1. Presented at: European Society for Blood and Marrow Transplantation-European Hematology Association 4th European CAR T-cell Meeting (virtual meeting); Feb. 10-12, 2022. Disclosures: van Meerten reports honoraria from Kite Pharma and…

Continue Reading Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

Novel CRISPR platform to decode the immune system

Date: 11th February 2022 The immune system is a critical biological network of processes that protects an organism from disease, and depends on the ability to distinguish self from non-self, a role driven by antigens.  In humans, T cells respond to antigen stimulation together with the production of cytokines however,…

Continue Reading Novel CRISPR platform to decode the immune system

Anti-CD19 CAR T-Cell Therapy for B-Cell Lymphoma

Researchers reported a favorable efficacy and manageable safety profile in anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for adults with B-cell lymphomas. Their data is presented in Frontiers in Genetics. Researchers, led by Wenyujing Zhou, aimed to determine the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy…

Continue Reading Anti-CD19 CAR T-Cell Therapy for B-Cell Lymphoma

In Focus: electroporation – RegMedNet

Transfection is the process of introducing foreign material – generally nucleic acids (DNA or RNA) – into cells. This allows for the study of gene function and protein expression in the context of the cell, or transformation of the cell into a potential cell therapy product such as a CAR-T….

Continue Reading In Focus: electroporation – RegMedNet

Novel CRISPR Tool Activates Instead of Editing Human Immune Cell Genes

Scientists at Gladstone Institutes and UC San Francisco (UCSF) say they have co-opted the CRISPR-Cas9 system to forcibly activate genes—rather than edit them—in human immune cells. The method, known as CRISPRa, lets them discover genes that play a role in immune cell biology more thoroughly and rapidly than previously possible,…

Continue Reading Novel CRISPR Tool Activates Instead of Editing Human Immune Cell Genes

Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17th,…

Continue Reading Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Researchers use CRISPR activation method to reveal “Rosetta Stone” of immune cell function

SAN FRANCISCO, CA—February 4, 2022—CRISPR genome editing has served as a powerful tool for deleting or altering DNA sequences and studying the resulting effect. Now, researchers at Gladstone Institutes and UC San Francisco (UCSF) have co-opted the CRISPR-Cas9 system to forcibly activate genes—rather than edit them—in human immune cells. The…

Continue Reading Researchers use CRISPR activation method to reveal “Rosetta Stone” of immune cell function

In Brief This Week: Innovent, Senhwa Biosciences, Oric Pharmaceuticals, Dizal Pharmaceutical

NEW YORK – Innovent this week said that pemigatinib (Pemazyre) was approved in Hong Kong as a treatment for locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. The approval was based on the Phase II FIGHT-202 study, which showed a 37 percent response rate for cholangiocarcinoma patients treated…

Continue Reading In Brief This Week: Innovent, Senhwa Biosciences, Oric Pharmaceuticals, Dizal Pharmaceutical

The Fabrication and Operation of a Continuous Flow, Micro-Electroporation System with Permeabilization Detection

Current therapeutic innovations, such as CAR-T cell therapy, are heavily reliant on viral-mediated gene delivery. Although efficient, this technique is accompanied by high manufacturing costs, which has brought about an interest in using alternative methods for gene delivery. Electroporation is an electro-physical, non-viral approach for the intracellular delivery of genes…

Continue Reading The Fabrication and Operation of a Continuous Flow, Micro-Electroporation System with Permeabilization Detection

FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Officials with the FDA have granted both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation to C-CAR039, a novel autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients…

Continue Reading FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

Stream episode Is CAR-T Therapy Superior to ASCT for Relapsed/Refractory DLBCL? by Healthcare Unfiltered podcast

published on 2022-01-11T11:58:44Z Continuing his ASH Annual Meeting coverage, Chadi invites Matt Maurer (@MaurerStats), MS, principal biostatistician, Mayo Clinic, and Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), to review the three prominent CAR-T studies in relapsed/refractory DLBCL presented at the meeting. Why…

Continue Reading Stream episode Is CAR-T Therapy Superior to ASCT for Relapsed/Refractory DLBCL? by Healthcare Unfiltered podcast

Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at…

Continue Reading Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

Brem Looks at Multiple Treatments for Patients With DLBCL

During a Targeted OncologyTM Case-Based Roundtable event, Elizabeth A. Brem, MD, an assistant professor in Division of Hematology/Oncology, Department of Medicine at UC Irvine Health in Los Angeles, CA, moderated a discussion about a 43-year-old woman with diffuse large B-cell lymphoma. Targeted Oncology™: What therapeutic options would you consider at…

Continue Reading Brem Looks at Multiple Treatments for Patients With DLBCL

Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

DISCUSSION QUESTIONS Do you foresee any barriers to using loncastuximab tesirine (Zynlonta) in diffuse large B-cell lymphoma (DLBCL)?​ If loncastuximab were covered by insurance, would you use it in the second line for patients who decline transplant?​ DEVA NATHAN, MD: I have different question. Are you willing to replace R-CHOP [rituximab…

Continue Reading Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

The Future of Targeted Therapies in DLBCL

In an interview with Targeted Oncology, Thomas Habermann, MD discusses the current unmet needs in the DLBCL space, along with the future of targeted therapies. While rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a highly effective therapy for diffuse large B-cell lymphoma (DLBCL). However, major unmet clinical needs still exist for patients with…

Continue Reading The Future of Targeted Therapies in DLBCL

Fate Therapeutics Highlights Positive Durability of

6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autologous CAR T-cell Therapy Achieve Complete Response…

Continue Reading Fate Therapeutics Highlights Positive Durability of

Should patients with DLBCL refractory to frontline RCHOP (or similar) or relapsing within

New data from ASH-2021 /NEJM ZUMA-7 trial (transformed FL were included in this study) Take home messages: Only 30% of patients who are treated with salvage chemotherapy will attain a complete response. Patients with a CR who proceed to ASCT do as well as patients on CAR-T upfront with good…

Continue Reading Should patients with DLBCL refractory to frontline RCHOP (or similar) or relapsing within

Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety. Real-world data on the use of tisagenlecleucel (Kymriah) showed greater efficacy and a favorable safety profile, according to updated findings from a study of the Center for…

Continue Reading Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

CAR-T therapy trials show promise for earlier use in lymphoma

Cell therapy, a relatively new and expensive treatment for certain blood cancers, might soon dislodge a decades-old standard of care for people with a common type of lymphoma that’s returned after initial drugs fail. Results from two late-stage studies, presented over the weekend at the American Society of Hematology’s annual…

Continue Reading CAR-T therapy trials show promise for earlier use in lymphoma

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas. Data will be…

Continue Reading Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

Treatment with tafasitamab (Monjuvi) and lenalidomide (Revlimid) provided an overall survival (OS) benefit vs standard options in a population of patients with autologous stem cell transplant (ASCT)–ineligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to findings from an expanded analysis of RE-MIND2 study (NCT04697160) that was presented at the 2021…

Continue Reading Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

DGAP-News: ???????MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL

​​​​​​​MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL 11.12.2021 / 18:00 The issuer is solely responsible for the content of this announcement. MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of…

Continue Reading DGAP-News: ???????MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Prof Brian Hill speaks to ecancer about a study he presented at the ASH 2021 meeting into potentially targetable pathways for CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL). He explains that the purpose of the study was to determine the impact of subtypes of DLBCL on the outcomes…

Continue Reading Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab

(RTTNews) – MorphoSys AG (MOR) and Incyte (INCY) announced the additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma or DLBCL. The treatments include polatuzumab vedotin plus…

Continue Reading Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab

Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab Combination Data

(RTTNews) – MorphoSys AG (MOR) and Incyte (INCY) announced the additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma or DLBCL. The treatments include polatuzumab vedotin plus…

Continue Reading Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab Combination Data

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The MarketWatch News Department was not involved in the creation of this content. December 11, 2021 (ACCESSWIRE via COMTEX) — – RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies – Results from the retrospective cohort analysis indicate significant overall survival improvement…

Continue Reading MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Liso-cel significantly improves outcomes in second-line DLBCL

December 11, 2021 2 min read Source/Disclosures Published by: Source: Kamdar M, et al. Abstract 91. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021. Disclosures: Kamdar reports consultant/advisory or speakers bureau roles with AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Genentech, Karyopharm…

Continue Reading Liso-cel significantly improves outcomes in second-line DLBCL

EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

December 11, 2021 3 min read Source/Disclosures Published by: Source: Locke FL, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021. Disclosures: Kite Pharma sponsored this study. Leslie reports advisory board, consultant or speakers bureau roles with AbbVie, AstraZeneca, BeiGene, Celgene/Bristol Myers…

Continue Reading EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

The combination of tafasitamab (Monjuvi) and lenalidomide (Revlimid) prolonged median overall survival (OS) compared with other standard options for autologous stem cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a closely matched expanded analysis of the observational, retrospective RE-MIND2 (NCT04697160) study presented at the…

Continue Reading Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

Choosing a Third-Line Treatment for Refractory DLBCL

DISCUSSION QUESTION What are the key factors that influence your decision making for third-line therapy? PAOLO CAIMI, MD: What are the key factors that influence your decision in choice of regimen for patients who are in the third-line therapy? Any comments about the things that you use when you’re thinking about…

Continue Reading Choosing a Third-Line Treatment for Refractory DLBCL

Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Courtesy Intellia Therapeutics Intellia Therapeutics is celebrating another first today as the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for NTLA-5001, its first wholly-owned ex vivo CRISPR genome editing candidate. NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML). Intellia…

Continue Reading Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Optimized two-step electroporation process to achieve efficient non-viral-mediated gene insertion into primary T cells

doi: 10.1002/2211-5463.13292. Online ahead of print. Affiliations Expand Affiliations 1 Cellectis Inc, 430E, 29th street, New York, NY, 10016, USA. 2 8 rue de la croix Jarry, 75013, Paris. Item in Clipboard Ming Yang et al. FEBS Open Bio. 2021. Show details Display options Display options Format AbstractPubMedPMID doi: 10.1002/2211-5463.13292. Online…

Continue Reading Optimized two-step electroporation process to achieve efficient non-viral-mediated gene insertion into primary T cells

Serotiny hiring Data Scientist / Bioinformatics Scientist

About Serotiny Serotiny is a company that is engaged in the discovery of proteins for cell therapies. It focuses on such proteins as CARs (chimeric antigen receptors) for the treatment of cancers and genetic disorders. Job Description Description Serotiny invents multi-domain proteins for gene and cell therapies including genome editors…

Continue Reading Serotiny hiring Data Scientist / Bioinformatics Scientist

Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the publication of data…

Continue Reading Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology

Caribou Biosciences Announces Publication of Data

Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou’s proprietary chRDNA technology for therapeutic applications BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the publication of data…

Continue Reading Caribou Biosciences Announces Publication of Data

Modification of endoglin-targeting nanoliposomes | IJN

Introduction Today, malignant tumors (cancer) still severely imperil human health and cause millions of global mortality rates.1,2 Deep-seated solid tumors are challenging to cure by most therapeutic tools, mainly blamed on the complex tumor microenvironment (TME).3,4 Adoptive cell therapy (ACT), as one of the effective immunotherapeutic means for cancer treatment,…

Continue Reading Modification of endoglin-targeting nanoliposomes | IJN

Industry Trends and Global Forecasts, 2021-2030

INTRODUCTION Clustered regularly interspaced short palindromic repeats (CRISPR) are a family of DNA sequences, which constitute a primitive immune system that is responsible for protecting prokaryotic cells from phage infections. New York, Aug. 24, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “CRISPR Based Therapeutics Market by…

Continue Reading Industry Trends and Global Forecasts, 2021-2030

Editas Medicine Presents Data on New SLEEK Gene Editing

SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells Data support SLEEK as an optimized approach to develop next generation cell therapy medicines CAMBRIDGE, Mass., Aug. 20, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today…

Continue Reading Editas Medicine Presents Data on New SLEEK Gene Editing

Can These Three Gene Therapies Get Us Closer to an HIV Cure?

Three research teams investigating HIV cures received a total of nearly $600,000 in grants from amfAR, The Foundation for AIDS Research. All three groups are exploring cutting-edge gene therapies as a possible way to eradicate the HIV reservoir and cure HIV. The HIV reservoir is one of the main obstacles…

Continue Reading Can These Three Gene Therapies Get Us Closer to an HIV Cure?

Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO | Rothwell, Figg, Ernst & Manbeck, P.C.

Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the most lucrative IPOs in gene-editing. In June 2021, Gene editing biotech Verve raised $267M in IPO proceeds and later added another $40 million after its financial underwriters opted to buy…

Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO | Rothwell, Figg, Ernst & Manbeck, P.C.